Senti Biosciences Holdings, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue - related party | $16 | $— |
| Operating expenses: | ||
| Research and development (including related party costs of $282 and $4,070 for the three months ended March 31, 2026 and 2025, respectively) | 5,281 | 9,281 |
| General and administrative | 6,233 | 7,116 |
| Gain on lease modification | (6,882) | — |
| Total operating expenses | 4,632 | 16,397 |
| Loss from operations | (4,616) | (16,397) |
| Other income: | ||
| Interest income | 101 | 394 |
| GeneFab sublease income - related party | 80 | 1,713 |
| Other income, net | 214 | 178 |
| Total other income | 395 | 2,285 |
| Net loss | $(4,221) | $(14,112) |
| Comprehensive loss | $(4,221) | $(14,112) |
| Basic and diluted net loss per share | $(0.14) | $(1.41) |
| Basic and diluted weighted-average number of shares used in computing net loss per share | 30,971,573 | 10,012,908 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.